Role of nanotechnology in pharmaceutical product development

Journal of Pharmaceutical Sciences

Volumn 96, Issue 10, 2007, Pages 2547-2565

  Devalapally, Harikrishna ^a   Chakilam, Ananthsrinivas ^b   Amiji, Mansoor M ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

^b VERTEX PHARMACEUTICALS   (United States)

Author keywords

Biopharmaceutics and pharmacokinetic properties; Dendrimers; Drug development; Liposomes; Micelles; Nanotechnology; New molecular entities; Polymeric nanoparticles

Indexed keywords

ALGINIC ACID; AMPHOTERICIN B; CAMPTOTHECIN; CHITOSAN; CLOTRIMAZOLE; CLOZAPINE; CYCLOSPORIN A; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ECONAZOLE; GANGLIOSIDE; INSULIN; ISONIAZID; KETOCONAZOLE; LIPOSOME; MACROGOL; MINOXIDIL; NANOPARTICLE; PACLITAXEL; PILOCARPINE; POLOXAMER; POLYMER; PREDNISOLONE HEMISUCCINATE; PYRAZINAMIDE; RIFAMPICIN; SALCATONIN; SULFATIDE; TOPOTECAN; ZIDOVUDINE;

DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; HUMAN; IN VIVO STUDY; IONIZATION; LIPOPHILICITY; LIPOSOMAL DELIVERY; NANOTECHNOLOGY; NONHUMAN; PATIENT COMPLIANCE; PHYSICAL CHEMISTRY; REVIEW;

EID: 35348970995     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20875     Document Type: Review

References (134)

1. Dimasi JA. 2001. New drug development in the United States from 1963 to 1999. Clin Pharmacol Ther 69:286-296.
2. DiMasi JA, Hansen RW, Grabowski HG. 2003. The price of innovation: New estimates of drug development costs. J Health Econ 22:151-185.
3. Rawlins MD. 2004. Cutting the cost of drug development? Nat Rev Drug Discov 3:360-364.
4. Service RF. 2004. Surviving the blockbuster syndrome. Science 303:1796-1799.
5. Hodgson J. 2001. ADMET-turning chemicals into drugs. Nat Biotechnol 19:722-726.
6. ME P. 1997. Development of new candidate drugs, Part 2: In vivo studies. Appl Clin Trials 6:42-46.
7. Lipinski CA. 2000. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 44:235-249.
8. Amidon GL, Lennernas H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420.
9. IR W. 2001. In search of a simple solution for complex molecules. Scrip Magazine: 9-11.
10. Gwinup G, Elias AN, Domurat ES. 1991. Insulin and C-peptide levels following oral administration of insulin in intestinal-enzyme protected capsules. Gen Pharmacol 22:243-246.
11. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. 2001. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3-26.
12. von Moltke LL, Greenblatt DJ, Schmider J, Harmatz JS, Shader RI. 1995. Metabolism of drugs by cytochrome P450 3A isoforms. Implications for drug interactions in psychopharmacology. Clin Pharmacokinet 29:33-43; discussion 43-34.
13. Li AP, Kaminski DL, Rasmussen A. 1995. Substrates of human hepatic cytochrome P450 3A4. Toxicology 104:1-8.
14. Benet LZ, Wu CY, Herbert MF, VJ W. 1996. Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug delivery. J Control Rel 39:139-143.
15. Obach RS. 2001. The prediction of human clearance from hepatic microsomal metabolism data. Curr Opin Drug Discov Devel 4:36-44.
16. Burke TG, Mishra AK, Wani MC, Wall ME. 1993. Lipid bilayer partitioning and stability of camptothecin drugs. Biochemistry 32:5352-5364.
17. Olivier JC. 2005. Drug transport to brain with targeted nanoparticles. NeuroRx 2:108-119.
18. Caliceti P, Veronese FM. 2003. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 55:1261-1277.
19. Zhou S, Chan E, Duan W, Huang M, Chen YZ. 2005. Drug bioactivation, covalent binding to target proteins and toxicity relevance. Drug Metab Rev 37:41-213.
20. Owens DE III, Peppas NA. 2006. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 307:93-102.
21. Tejada-Berges T, Granai CO, Gordinier M, Gajewski W. 2002. Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer. Expert Rev Anticancer Ther 2:143-150.
22. Gradishar WJ. 2006. Albumin-bound paclitaxel: A next-generation taxane. Expert Opin Pharmacother 7:1041-1053.
23. Möschwitzer JMüller RH. 2006. New method for the effective production of ultrafine drug nanocrystals. J Nanosci Nanotechnol 6:3145-3153.
24. Schek RM, Hollister SJ, Krebsbach PH. 2004. Delivery and protection of adenoviruses using biocompatible hydrogels for localized gene therapy. Mol Ther 9:130-138.
25. Carrstensen H, Muller RH, Muller BW. 1992. Particle size, surface hydrophobicity and interaction with serum of parenteral fat emulsions and model drug carriers as parameters related to RES uptake. Clin Nutr 11:289-297.
26. Norman ME, Williams P, Illum L. 1992. Human serum albumin as a probe for surface conditioning (opsonization) of block copolymer-coated microspheres. Biomaterials 13:841-849.
27. Moghimi SM, Hedeman H, Muir IS, Illum L, Davis SS. 1993. An investigation of the filtration capacity and the fate of large filtered sterically-stabilized microspheres in rat spleen. Biochim Biophys Acta 1157:233-240.
28. Roser M, Fischer D, Kissel T. 1998. Surface-modified biodegradable albumin nano- and microspheres. II: Effect of surface charges on in vitro phagocytosis and biodistribution in rats. Eur J Pharm Biopharm 46:255-263.
29. Gref R, Domb A, Quellec P, Blunk T, Miller R, Verbavatz JM, Langer R. 1995. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv Drug Deliv Rev 16:215-233.
30. Duncan R, Spreafico F. 1994. Polymer conjugates. Pharmacokinetic considerations for design and development. Clin Pharmacokinet 27:290-306.
31. LaVan DA, Lynn DM, Langer R. 2002. Moving smaller in drug discovery and delivery. Nat Rev Drug Discov 1:77-84.
32. Duncan R. 2003. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2:347-360.
33. Torchilin VP. 2005. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4:145-160.
34. Sahoo SK, Labhasetwar V. 2003. Nanotech approaches to drug delivery and imaging. Drug Discov Today 8:1112-1120.
35. Allen TM. 1994. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol Sci 15:215-220.
36. Allen TM, Chonn A. 1987. Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett 223:42-46.
37. Papahadjopoulos D, Gabizon A. 1987. Targeting of liposomes to tumor cells in vivo. Ann N Y Acad Sci 507:64-74.
38. Gabizon A, Papahadjopoulos D. 1988. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA 85:6949-6953.
39. Allen TM, Hansen C, Rutledge J. 1989. Liposomes with prolonged circulation times: Factors affecting uptake by reticuloendothelial and other tissues. Biochim Biophys Acta 981:27-35.
40. Xu JP, Ji J, Chen WD, Shen JC. 2005. Novel biomimetic polymersomes as polymer therapeutics for drug delivery. J Control Release 107:502-512.
41. Harris JM, Chess RB. 2003. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2:214-221.
42. Allen TM, Cullis PR. 2004. Drug delivery systems: Entering the mainstream. Science 303:1818-1822.
43. Cabanes A, Briggs KE, Gokhale PC, Treat JA, Rahman A. 1998. Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel. Int J Oncol 12:1035-1040.
44. Kirby C, Gregoriadis G. 1980. The effect of the cholesterol content of small unilamellar liposomes on the fate of their lipid components in vitro. Life Sci 27:2223-2230.
45. Gabizon A, Shmeeda H, Barenholz Y. 2003. Pharmacokinetics of pegylated liposomal Doxorubicin: Review of animal and human studies. Clin Pharmacokinet 42:419-436.
46. Sliedregt LA, Rensen PC, Rump ET, van Santbrink PJ, Bijsterbosch MK, Valentijn AR, van der Marel GA, van Boom JH, van Berkel TJ, Biessen EA. 1999. Design and synthesis of novel amphiphilic dendritic galactosides for selective targeting of liposomes to the hepatic asialoglycoprotein receptor. J Med Chem 42:609-618.
47. Barza M, Stuart M, Szoka F, Jr. 1987. Effect of size and lipid composition on the pharmacokinetics of intravitreal liposomes. Invest Ophthalmol Vis Sci 28:893-900.
48. Hawley AE, Davis SS, L I. 1995. Targeting of colloids to lymph nodes: Influence of lymphatic physiology and colloidal characteristics. Adv Drug Deliv Rev 17:129-148.
49. Tumer A, Kirby C, Senior J, Gregoriadis G. 1983. Fate of cholesterol-rich liposomes after subcutaneous injection into rats. Biochim Biophys Acta 760:119-125.
50. Allen TM, Hansen CB, Guo LS. 1993. Subcutaneous administration of liposomes: A comparison with the intravenous and intraperitoneal routes of injection. Biochim Biophys Acta 1150:9-16.
51. Oussoren C, Storm G. 1997. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection: III. Influence of surface modification with poly(ethyleneglycol). Pharm Res 14:1479-1484.
52. Oussoren C, Zuidema J, Crommelin DJ, Storm G. 1997. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid compostion and lipid dose. Biochim Biophys Acta 1328:261-272.
53. Fetterly GJ, Straubinger RM. 2003. Pharmacokinetics of paclitaxel-containing liposomes in rats. AAPS PharmSci 5:E32.
54. Teshima M, Fumoto S, Nishida K, Nakamura J, Ohyama K, Nakamura T, Ichikawa N, Nakashima M, Sasaki H. 2006. Prolonged blood concentration of prednisolone after intravenous injection of liposomal palmitoyl prednisolone. J Control Release 112:320-328.
55. Khan MA, Owais M. 2006. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model. J Antimicrob Chemother 58:125-132.
56. Wu J, Liu Q, Lee RJ. 2006. A folate receptor-targeted liposomal formulation for paclitaxel. Int J Pharm 316:148-153.
57. Moghimi SM, Hunter AC, Murray JC. 2001. Long-circulating and target-specific nanoparticles: Theory to practice. Pharmacol Rev 53:283-318.
58. Moghimi SM, Hunter AC. 2000. Poloxamers and poloxamines in nanoparticle engineering and experimental medicine. Trends Biotechnol 18:412-420.
59. Lasic DD, Martin FJ, Gabizon A, Huang SK, Papahadjopoulos D. 1991. Sterically stabilized liposomes: A hypothesis on the molecular origin of the extended circulation times. Biochim Biophys Acta 1070:187-192.
60. Amiji M, Park K. 1992. Prevention of protein adsorption and platelet adhesion on surfaces by PEO/PPO/PEO triblock copolymers. Biomaterials 13:682-692.
61. Moghimi SM, Szebeni J. 2003. Stealth liposomes and long circulating nanoparticles: Critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 42:463-478.
62. Torchilin VP, VS T. 1995. Which polymers can make nanoparticulate drug carrier long circulating? Adv Drug Delivery Rev 16:141-155.
63. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. 1994. Biodegradable long-circulating polymeric nanospheres. Science 263:1600-1603.
64. Lockman PR, Mumper RJ, Khan MA, DD A. 2002. Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm 28:1-13.
65. Gupta PK, Hung CT, Perrier DG. 1987. Quantitation of the release of doxorubicin from colloidal dosage forms using dynamic dialysis. J Pharm Sci 76:141-145.
66. Kreuter J. 1994. Nanoparticles. In: Kreuter J, editor. Colloidal drug delivery systems. New York, NY: Marcel Dekker, Inc. pp 219-342.
67. Gref R, Luck M, Quellec P, Marchand M, Dellacherie E, Harnisch S, Blunk T, Muller RH. 2000. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): Influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces 18:301-313.
68. Otsuka H, Nagasaki Y, Kataoka K. 2003. PEGylated nanoparticles for biological and pharmaceutical applications. Adv Drug Deliv Rev 55:403-419.
69. Tan JS, Butterfield DE, Voycheck CL, Caldwell KD, Li JT. 1993. Surface modification of nanoparticles by PEO/PPO block copolymers to minimize interactions with blood components and prolong blood circulation in rats. Biomaterials 14:823-833.
70. Kaul G, Amiji M. 2002. Long-circulating poly(ethylene glycol)-modified gelatin nanoparticles for intracellular delivery. Pharm Res 19:1061-1067.
71. Bibby DC, Talmadge JE, Dalal MK, Kurz SG, Chytil KM, Barry SE, Shand DG, Steiert M. 2005. Pharmacokinetics and biodistribution of RGD-targeted doxorubicin-loaded nanoparticles in tumor-bearing mice. Int J Pharm 293:281-290.
72. Reddy LH, RS M. 2004. Pharmacokinetics and biodistribution studies of Doxorubicin loaded poly(butyl cyanoacrylate) nanoparticles synthesized by two different techniques. Biomed Papers 148:161-166.
73. Reddy LH, Sharma RK, Chuttani K, Mishra AK, Murthy RR. 2004. Etoposide-incorporated tripalmitin nanoparticles with different surface charge: Formulation, characterization, radiolabeling, and biodistribution studies. AAPS J 6:e23.
74. Heiati H, Awashi R, NC P. 1998. Solid lipid nanoparticles as drug carriers II. Plasma stability and biodistribution of solid lipid nanoparticles containing the lipophilic prodrug 3′-azido-3′-deoxythymidine palmitate in mice. Int J Pharm 174:71-80.
75. Manjunath K, Venkateswarlu V. 2005. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release 107:215-228.
76. Barichello JM, Morishita M, Takayama K, Nagai T. 1999. Absorption of insulin from pluronic F-127 gels following subcutaneous administration in rats. Int J Pharm 184:189-198.
77. Pan Y, Li YJ, Zhao HY, Zheng JM, Xu H, Wei G, Hao JS, Cui FD. 2002. Bioadhesive polysaccharide in protein delivery system: Chitosan nanoparticles improve the intestinal absorption of insulin in vivo. Int J Pharm 249:139-147.
78. Kaul G, Amiji M. 2005. Tumor-targeted gene delivery using poly(ethylene glycol)-modified gelatin nanoparticles: In vitro and in vivo studies. Pharm Res 22:951-961.
79. Kaul G, Amiji M. 2004. Biodistribution and targeting potential of poly(ethylene glycol)-modified gelatin nanoparticles in subcutaneous murine tumor model. J Drug Target 12:585-591.
80. Kommareddy S, Amiji M. 2005. Preparation and evaluation of thiol-modified gelatin nanoparticles for intracellular DNA delivery in response to glutathione. Bioconjug Chem 16:1423-1432.
81. Shenoy D, Little S, Langer R, Amiji M. 2005. Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs. 1. In vitro evaluations. Mol Pharm 2:357-366.
82. Shenoy D, Little S, Langer R, Amiji M. 2005. Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: Part 2. In vivo distribution and tumor localization studies. Pharm Res 22:2107-2114.
83. A-L U. 1997. In vitro absorption studies and their relevance to absorption from the GI tract. Drug Dev Ind Pharm 23:879-892.
84. Chan OH, Schmid HL, Stilgenbauer LA, Howson W, Horwell DC, Stewart BH. 1998. Evaluation of a targeted prodrug strategy of enhance oral absorption of poorly water-soluble compounds. Pharm Res 15:1012-1018.
85. J D. 1998. Oral drug delivery technology: Addressing the solubility/permeability paradigm. Pharm Technol 22:68-80.
86. Florence AT, Jani PU. 1993.Particulate delivery: The challenge of the oral route, ed., New York: Marcel Dekker.
87. Swartz MA. 2001. The physiology of the lymphatic system. Adv Drug Deliv Rev 50:3-20.
88. Hargrove JT, Maxson WS, Wentz AC. 1989. Absorption of oral progesterone is influenced by vehicle and particle size. Am J Obstet Gynecol 161:948-951.
89. Englund DE, Johansson ED. 1981. Oral versus vaginal absorption in oestradiol in postmenopausal women. Effects of different particles sizes. Ups J Med Sci 86:297-307.
90. Watari N, Funaki T, Aizawa K, Kaneniwa N. 1983. Nonlinear assessment of nitrofurantoin bioavailability in rabbits. J Pharmacokinet Biopharm 11:529-545.
91. Shastri S, Mroszczak E, Prichard RK, Parekh P, Nguyen TH, Hennessey DR, Schiltz R. 1980. Relationship among particle size distribution, dissolution profile, plasma values, and anthelmintic efficacy of oxfendazole. Am J Vet Res 41:2095-2101.
92. Nimmerfall F, Rosenthaler J. 1980. Dependence of area under the curve on proquazone particle size and in vitro dissolution rate. J Pharm Sci 69:605-607.
93. Kondo N, Iwao T, Kikuchi M, Shu H, Yamanouchi K, Yokoyama K, Ohyama K, S O. 1993b. Pharmacokinetics of a micronized, poorly water-soluble drug, HO-221, in experimental animals. Biol Pharm Bull 16:796-800.
94. Kondo N, Iwao T, Masuda H, Yamanouchi K, Ishihara Y, Yamada N, Haga T, Ogawa Y, K Y. 1993a. Improved oral absorption of a poorly water-soluble drug, HO-221, by wet-bead milling producing particles in submicron region. Chem Pharm Bull 41:737-740.
95. Kondo N, Iwao T, Hirai K, Fukuda M, Yamanouchi K, Yokoyama K, Miyaji M, Ishihara Y, Kon K, Ogawa Y, Mayumi T. 1994. Improved oral absorption of enteric coprecipitates of a poorly soluble drug. J Pharm Sci 83:566-570.
96. Pandey R, Ahmad Z, Sharma S, Khuller GK. 2005. Nano-encapsulation of azole antifungals: Potential applications to improve oral drug delivery. Int J Pharm 301:268-276.
97. Ubrich N, Schmidt C, Bodmeier R, Hoffman M, Maincent P. 2005. Oral evaluation in rabbits of cyclosporin-loaded Eudragit RS or RL nanoparticles. Int J Pharm 288:169-175.
98. Sakuma S, Suzuki N, Sudo R, Hiwatari K, Kishida A, Akashi M. 2002. Optimized chemical structure of nanoparticles as carriers for oral delivery of salmon calcitonin. Int J Pharm 239:185-195.
99. Sakuma S, Suzuki N, Kikuchi H, Hiwatari K, Arikawa K, Kishida A, M A. 1997. Absorption enhancement of orally administered salmon calcitonin by polystyrene nanoparticles having poly(N-isopropylacrylamide) branches on their surfaces. Int J Pharm 158:69-78.
100. Mesiha MS, Sidhom MB, Fasipe B. 2005. Oral and subcutaneous absorption of insulin poly(isobutylcyanoacrylate) nanoparticles. Int J Pharm 288:289-293.
101. Shim J, Seok Kang H, Park WS, Han SH, Kim J, Chang IS. 2004. Transdermal delivery of mixnoxidil with block copolymer nanoparticles. J Control Release 97:477-484.
102. Pandey R, Sharma A, Zahoor A, Sharma S, Khuller GK, Prasad B. 2003. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother 52:981-986.
103. Sharma A, Sharma S, Khuller GK. 2004. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J Antimicrob Chemother 54:761-766.
104. Kataoka K, Kwon G, Yokoyama M, Okano T, Y S. 1992. Block copolymer micelles as vehicles for drug delivery. J Control Release 24:119-132.
105. Kwon GS, Okano T. 1996. Polymeric micelles as new drug carriers. Adv Drug Deliv Rev 16:107-116.
106. Kabanov A, V A. 2002. Pluronic block copolymers in drug delivery: From micellar nanocontainers to biological response modifiers. Crit Rev Ther Drug Carri Syst 19:1-72.
107. Hammad MA, Muller BW. 1998. Solubility and stability of tetrazepam in mixed micelles. Eur J Pharm Sci 7:49-55.
108. Torchilin VP, Lukyanov AN, Gao Z, Papahadjopoulos-Sternberg B. 2003. Immunomicelles: Targeted pharmaceutical carriers for poorly soluble drugs. Proc Natl Acad Sci USA 100:6039-6044.
109. Matsumura Y, Hamaguchi T, Ura T, Muro K, Yamada Y, Shimada Y, Shirao K, Okusaka T, Ueno H, Ikeda M, Watanabe N. 2004. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br J Cancer 91:1775-1781.
110. Kim SC, Kim DW, Shim YH, Bang JS, Oh HS, Wan Kim S, Seo MH. 2001. In vivo evaluation of polymeric micellar paclitaxel formulation: Toxicity and efficacy. J Control Release 72:191-202.
111. Yoo HS, Park TG. 2004. Folate receptor targeted biodegradable polymeric doxorubicin micelles. J Control Release 96:273-283.
112. Batrakova EV, Li S, Li Y, Alakhov VY, Elmquist WF, Kabanov AV. 2004. Distribution kinetics of a micelle-forming block copolymer Pluronic P85. J Control Release 100:389-397.
113. Watanabe M, Kawano K, Yokoyamab M, Opanasopit P, Okanoc T, Y M. 2006. Preparation of camptothecin-loaded polymeric micelles and evaluation of their incorporation and circulation stability. Int J Pharm 308:183-189.
114. Guo J, Wu T, Ping Q, Chen Y, Shen J, Jiang G. 2005. Solubilization and pharmacokinetic behaviors of sodium cholate/lecithin-mixed micelles containing cyclosporine A. Drug Deliv 12:35-39.
115. Cabrala H, Nishiyamab N, Okazakia S, Koyamab H, K K. 2005. Preparation and biological properties of dichloro(1,2-diaminocyclohexane)platinum(II) (DACHPt)-loaded polymeric micelles. J Control Release 101:223-232.
116. Pepíc I, Jalsenjak N, Jalsenjak I. 2004. Micellar solutions of triblock copolymer surfactants with pilocarpine. Int J Pharm 27257:57-64.
117. Jones MC, Ranger M, JC L. 2003. pH-sensitive unimolecular polymeric micelles: Synthesis of a novel drug carrier. Bioconjug Chem 4:774-781.
118. Helms B, EW M. 2000. Chemistry. Dendrimers at work. Science 313:929-930.
119. Seymour LW, Miyamoto Y, Maeda H, Brereton M, Strohalm J, Ulbrich K, Duncan R. 2000. Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier. Eur J Cancer 31A:766-770.
120. Svenson S, Tomalia DA. 2005. Dendrimers in biomedical applications - reflections on the field. Adv Drug Deliv Rev 57:2106-2129.
121. Duncan R, Izzo L. 2005. Dendrimer biocompatibility and toxicity. Adv Drug Deliv Rev 57:2215-2237.
122. Nishikawa M, Takakura Y, Hashida M. 1996. Pharmacokinetic evaluation of polymeric carriers. Adv Drug Deliv Rev 21:135-155.
123. Matsumura Y, Maeda H. 1986. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46:6387-6392.
124. Duncan R. 1999. Polymer conjugates for tumour targeting and intracytoplasmic delivery. The EPR effect as a common gateway? Pharm Sci Technol Today 2:441-449.
125. Lee CC, Mac Kay JA, Frechet JM, Szoka FC. 2005. Designing dendrimers for biological applications. Nat Biotechnol 23:1517-1526.
126. Malik N, Wiwattanapatapee R, Klopsch R, Lorenz K, Frey H, Weener JW, Meijer EW, Paulus W, Duncan R. 2000. Relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of I-labelled polyamidoamine dendrimers in vivo. J Control Release 65:133-148.
127. Margerum LD, Campion BK, Koo M, Shargill N, Lai JJ, Marumoto A, Sontum PC. 1997. Gadolinium (III) DO3A macrocycles and polyethylene glycol coupled to dendrimers-Effect of molecular weight on physical and biological properties of macromolecular resonance imaging contrast agents. J Alloys Compounds 249:185-190.
128. Malik N, Evagorou EG, Duncan R. 1999. Dendrimer-platinate: A novel approach to cancer chemotherapy. Anticancer Drugs 10:767-776.
129. Asthana A, Chauhan AS, Diwan PV, NK J. 2005. Poly(amidoamine) (PAMAM) dendritic nanostructures for controlled site-specific delivery of acidic anti-inflammatory active ingredient. AAPS PharmSciTech 6:E536-542.
130. Kukowska-Latallo JF, Kimberly A, Candido KA, Cao Z, Nigavekar SS, Majoros IJ, Thomas TP, Balogh LP, Khan MK, Baker JR, Jr. 2005. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial Cancer. Cancer Res 65:12.
131. Kobayashi H, Kawamoto S, Jo SK, Bryant HL, Jr.,Brechbiel MW, Star RA. 2003. Macromolecular MRI contrast agents with small dendrimers: Pharmacokinetic differences between sizes and cores. Bioconjug Chem 14:388-394.
132. Khandare J, Kolhe P, Pillai O, Kannan S, Lieh-Lai M, Kannan RM. 2005. Synthesis, cellular transport, and activity of polyamidoamine dendrimer-methylprednisolone conjugates. Bioconjug Chem 16:330-337.
133. Okuda T, Kawakami S, Maeie T, Niidome T, Yamashita F, Hashida M. 2006. Biodistribution characteristics of amino acid dendrimers and their PEGylated derivatives after intravenous administration. J Control Release 114:69-77.
134. Yang H, Morris JJ, Lopina ST. 2004. Polyethylene glycol-polyamidoamine dendritic micelle as solubility enhancer and the effect of the length of polyethylene glycol arms on the solubility of pyrene in water. J Colloid Interface Sci 273:148-154.